Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 1, 2023
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
[ Wed, Mar 01st 2023
] - WOPRAI
Vamil Divan Initiated (ANIP) at Strong Buy and Held Target at $55 on, Mar 1st, 2023
Vamil Divan of Guggenheim, Initiated "ANI Pharmaceuticals, Inc." (ANIP) at Strong Buy and Held Target at $55 on, Mar 1st, 2023.
Vamil has made no other calls on ANIP in the last 4 months.
There is 1 other peer that has a rating on ANIP. Out of the 1 peers that are also analyzing ANIP, 0 agree with Vamil's Rating of Hold.
This is the rating of the analyst that currently disagrees with Vamil
- Oren Livnat of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $50 on, Tuesday, February 21st, 2023
